Dawson James Reiterates Buy Rating on Can-Fite BioPharma (CANF) on Complete Response in Liver Cancer
Tweet Send to a Friend
Dawson James analyst Jason Kolbert reiterated a Buy rating and $5.00 price target on Can-Fite BioPharma (NYSE: CANF) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
